Check out what we have in store for you in the November Newsletter
Here we are in the fall and only days away from the election—finally! Anyway, this issue of the HCV Advocate newsletter is, in my opinion, one of our best. I hope you think so too!
Please find the following articles:
- HealthWise – Talking to Your Doctor About Hepatitis C Treatment, Getting What’s Best for You by Lucinda K. Porter, RN — Lucinda discusses the importance of working with your doctor, how to fight insurance denials, helpful resources, and other important information.
- HCV Drugs by Alan Franciscus — I discuss two studies—the first one is about Gilead’s salvage therapy to treat the small percentage of people who do not respond to the current standard of care. The second study is an AbbVie study that treated HCV genotype 1b patients for 8 weeks that resulted in very high cure rates.
- Snapshots by Alan Franciscus — I reviewed two studies: The first one is a study conducted in the Veterans Affairs National Health Care System that evaluated all of the current (at that time) direct-acting antivirals (DAAs) medications to understand the cure rates and the ‘real-world’ results vs. results from the clinical trials.
- Under the Umbrella HCV Community Education – Teaching and Learning by Matthew Zielske—Matthew shares his ideas and experiences as an educator. Matthew has conducted our Train-the-Trainer Workshops in Indiana and Kentucky and we hope to expand the workshops throughout the United States in 2017.
- HCV Drug Pipeline Our Drug Pipeline has been updated with the information about the Gilead data from this month’s newsletter.
- What’s Up!
- Check out our new Easy C fact sheet on the importance of testing for hepatitis B before initiating HCV direct-acting antiviral therapy.
- We have also added many resources to our Trainers page including 2 slide sets—a short presentation and the longer that one we include in our Train-the-Trainer workshops. We also have a list of resources.
Don’t forget to join us for coverage of the Liver Meeting. We will be covering it on our News and Pipeline blog and in the December 2016 and January 2017 HCV Advocate Newsletter.
Alan and the staff of the HCV Advocate Newsletter
Recently I went on a first date — a stroll in a city park — that went rather well. We had so much in common, from a love of reading to a history of youthful troublemaking. If I wasn’t convinced already he was someone I could relate to, my new friend shared that he’d been cured of Hepatitis C.
I could hardly believe it. Instead of having to awkwardly explain my medical history, I’d met someone who shares it. It was a first. The only other time I’d met people who’d been cured of Hepatitis C, I was at an event at Johns Hopkins celebrating the first 1,000 successes of the new drugs. Some of my fellow drug program participants had gotten it from blood transfusions, some from vaccinations in the military. Some had no idea how.
In any case, our unicorn status can’t go on much longer. According to the director of the Centers for Disease Control, who spoke that day, one in 30 baby boomers has Hepatitis C. Forty percent of those people will die of the virus, at an average age of 59.